IHS Chemical Week

Regions :: Western Europe :: U.K.

AstraZeneca acquires ADC technology firm Spirogen

3:27 AM MDT | October 16, 2013 | Deepti Ramesh

AstraZeneca (London) says that its biologics R&D arm, MedImmune (Gaithersburg, MD), has acquired Spirogen (London), a privately held biotech company focused on antibody-drug conjugate (ADC) technology for use in oncology. MedImmune has also entered into a collaboration agreement with ADC Therapeutics (Lausanne, Switzerland) to jointly develop two of ADC Therapeutics’ ADC programs in preclinical development, AstraZeneca says. MedImmune will also make an equity investment in ADC Therapeutics, which has an existing licensing agreement with Spirogen...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa